IS7189A - Sómatóstatín- eða bombesínhliðstæðusamstæður til greiningar eða meðferðar og notkun þeirra - Google Patents

Sómatóstatín- eða bombesínhliðstæðusamstæður til greiningar eða meðferðar og notkun þeirra

Info

Publication number
IS7189A
IS7189A IS7189A IS7189A IS7189A IS 7189 A IS7189 A IS 7189A IS 7189 A IS7189 A IS 7189A IS 7189 A IS7189 A IS 7189A IS 7189 A IS7189 A IS 7189A
Authority
IS
Iceland
Prior art keywords
somatostatin
diagnosis
treatment
bombesin analogues
bombesin
Prior art date
Application number
IS7189A
Other languages
English (en)
Inventor
H. Coy David
A. Fuselier Joseph
A. Murphy William
Sun Lichun
Original Assignee
The Administrators Of The Tulane Educational Fund
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Administrators Of The Tulane Educational Fund filed Critical The Administrators Of The Tulane Educational Fund
Publication of IS7189A publication Critical patent/IS7189A/is

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/58—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. poly[meth]acrylate, polyacrylamide, polystyrene, polyvinylpyrrolidone, polyvinylalcohol or polystyrene sulfonic acid resin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/083—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins the peptide being octreotide or a somatostatin-receptor-binding peptide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Molecular Biology (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Percussion Or Vibration Massage (AREA)
IS7189A 2001-09-21 2004-03-19 Sómatóstatín- eða bombesínhliðstæðusamstæður til greiningar eða meðferðar og notkun þeirra IS7189A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US32385101P 2001-09-21 2001-09-21
PCT/US2002/030143 WO2003028527A2 (en) 2001-09-21 2002-09-20 Diagnostic or therapeutic somatostatin or bombesin analog conjugates and uses thereof

Publications (1)

Publication Number Publication Date
IS7189A true IS7189A (is) 2004-03-19

Family

ID=23260992

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7189A IS7189A (is) 2001-09-21 2004-03-19 Sómatóstatín- eða bombesínhliðstæðusamstæður til greiningar eða meðferðar og notkun þeirra

Country Status (16)

Country Link
US (1) US7326685B2 (is)
EP (1) EP1435826A4 (is)
JP (1) JP4799820B2 (is)
KR (1) KR20040047846A (is)
CN (1) CN1589151A (is)
AU (1) AU2002341792B2 (is)
BR (1) BR0212897A (is)
CA (1) CA2461099A1 (is)
IL (2) IL160993A0 (is)
IS (1) IS7189A (is)
MX (1) MXPA04002621A (is)
NO (1) NO20041186L (is)
NZ (1) NZ532204A (is)
PL (1) PL369336A1 (is)
WO (1) WO2003028527A2 (is)
ZA (1) ZA200402698B (is)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6721705B2 (en) * 2000-02-04 2004-04-13 Webley Systems, Inc. Robust voice browser system and voice activated device controller
MXPA04008419A (es) 2002-03-01 2004-11-26 Univ Tulane Conjugados de agentes terapeuticos o citotoxicos y peptidos biologicamente activos.
US8060626B2 (en) * 2008-09-22 2011-11-15 Sony Computer Entertainment America Llc. Method for host selection based on discovered NAT type
US7977049B2 (en) * 2002-08-09 2011-07-12 President And Fellows Of Harvard College Methods and compositions for extending the life span and increasing the stress resistance of cells and organisms
EP1624884A4 (en) * 2003-04-22 2009-08-05 Ipsen Pharma SOMATOSTATIN VECTORS
EP2236131A3 (en) * 2003-07-01 2011-03-02 President and Fellows of Harvard College Sirt1 modulators for manipulating cell/organism lifespan/stress response
US20060025337A1 (en) * 2003-07-01 2006-02-02 President And Fellows Of Harvard College Sirtuin related therapeutics and diagnostics for neurodegenerative diseases
JP2007527418A (ja) 2003-12-29 2007-09-27 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 肥満及びインシュリン耐性障害を治療又は防止するための組成物
US8017634B2 (en) * 2003-12-29 2011-09-13 President And Fellows Of Harvard College Compositions for treating obesity and insulin resistance disorders
US20050255045A1 (en) * 2004-05-13 2005-11-17 Woltering Eugene A Surgical marking composition and method
CA2467321A1 (en) * 2004-05-14 2005-11-14 Paul J. Santerre Polymeric coupling agents and pharmaceutically-active polymers made therefrom
EP1744787A4 (en) * 2004-05-14 2011-04-06 Interface Biologics Inc POLYMER COUPLING AGENTS AND PHARMACEUTICALLY ACTIVE POLYMERS MANUFACTURED THEREOF
EP1765316A2 (en) * 2004-06-16 2007-03-28 The President and Fellows of Harvard College Methods and compositions for modulating bax-ku70-mediated apoptosis
US20060014705A1 (en) * 2004-06-30 2006-01-19 Howitz Konrad T Compositions and methods for selectively activating human sirtuins
WO2006138418A2 (en) * 2005-06-14 2006-12-28 President And Fellows Of Harvard College Improvement of cognitive performance with sirtuin activators
AU2006259261B2 (en) * 2005-06-16 2013-06-13 Myrexis, Inc. Pharmaceutical compositions and use thereof
EP1987846B1 (en) * 2006-02-23 2016-07-13 Adeka Corporation Diagnostic marker
DE102006035083A1 (de) * 2006-07-28 2008-01-31 medac Gesellschaft für klinische Spezialgeräte mbH Proteinbindende Methotrexat-Derivate und diese enthaltende Arzneimittel
PL2076535T3 (pl) 2006-10-16 2013-08-30 Salk Inst Biological Studies Antagoniści somatostatyny selektywni względem receptora (SSTR2)
US8691761B2 (en) 2006-10-16 2014-04-08 Jean E. F. Rivier Somatostatin receptor 2 antagonists
RU2457218C2 (ru) * 2006-10-20 2012-07-27 Ипсен Фарма С.А.С. Конъюгаты цитотоксических средств с пептидами
CA2720989A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Methods for treating cancer
WO2008124824A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Dosages and methods for the treatment of cancer
WO2008124828A1 (en) * 2007-04-10 2008-10-16 Myriad Genetics, Inc. Methods for treating vascular disruption disorders
AU2008236994A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Method of treating melanoma
AU2008236993A1 (en) * 2007-04-10 2008-10-16 Myrexis, Inc. Method of treating brain cancer
CN108514638A (zh) 2011-02-17 2018-09-11 杜兰教育基金委员会 多组分组合物以及它们的用途
US10351626B2 (en) 2013-03-14 2019-07-16 The Scripps Research Institute Targeting agent antibody conjugates and uses thereof
JP6951826B2 (ja) 2016-02-04 2021-10-20 ザ スクリプス リサーチ インスティテュート ヒト化抗ｃｄ３抗体、その複合体、およびその使用
WO2017136943A1 (en) 2016-02-09 2017-08-17 Cdrd Ventures Inc. Somatostatin receptor antagonist compounds and methods of using the same
AU2017238246B2 (en) 2016-03-24 2021-04-01 The Administrators Of The Tulane Educational Fund Conjugates of tacrolimus, their compositions, and their uses
US12485191B2 (en) * 2017-11-28 2025-12-02 Board Of Regents Of The Univeristy Of Nebraska Radiopharmaceuticals and methods of use thereof
CA3087898A1 (en) 2018-02-02 2019-08-08 Ripple Therapeutics Corporation Glass formulations comprising steroid dimers and uses thereof
AU2019234523B2 (en) * 2018-03-15 2024-09-12 Osaka University Pharmaceutical composition containing 211At-labeled amino acid derivative, and method for producing said pharmaceutical composition
WO2020154815A1 (en) 2019-02-01 2020-08-06 Ripple Therapeutics Corporation Crystalline forms of dexamethasone dimers and uses thereof
US12509469B2 (en) 2019-08-07 2025-12-30 Ripple Therapeutics Corporation Compositions and methods for the treatment of pain and dependence disorders
JP2023524494A (ja) 2020-05-01 2023-06-12 リップル セラピューティクス コーポレーション 眼障害を処置するためのヘテロ二量体組成物と方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904642A (en) 1985-09-12 1990-02-27 The Administrators Of The Tulane Educational Fund Therapeutic somatostatin analogs
US4812590A (en) 1987-06-25 1989-03-14 Merck & Co., Inc. Carbamates of 4-hydroxyanisole as prodrugs for chemotherapy of melanoma
US5073541A (en) 1987-11-18 1991-12-17 Administrators Of The Tulane Educational Fund Treatment of small cell lung cancer with somatostatin analogs
US5753627A (en) 1988-12-05 1998-05-19 Novartis Ag Use of certain complexed somatostatin peptides for the invivo imaging of somatostatin receptor-positive tumors and metastasis
US5633263A (en) 1989-04-26 1997-05-27 The Administrators Of The Tulane Educational Fund Linear somatostatin analogs
DK0436005T3 (da) 1989-07-20 1995-07-03 Sandoz Ltd Mærkede polypeptidderivater
DK0450480T3 (da) * 1990-04-06 1995-08-14 Univ Tulane Somatostatinaloger
US5443815A (en) 1991-11-27 1995-08-22 Diatech, Inc. Technetium-99m labeled peptides for imaging
US5411943A (en) 1992-02-25 1995-05-02 Biomeasure, Inc. Hepatoma treatment with somatostatin analogs
US5620675A (en) 1992-06-23 1997-04-15 Diatech, Inc. Radioactive peptides
US5597894A (en) * 1995-06-05 1997-01-28 The Louisiana State University Medical Center Foundation Multi-tyrosinated somatostatin analogs
US6051554A (en) * 1995-06-07 2000-04-18 Peptor Limited Conformationally constrained backbone cyclized somatostatin analogs
US5770687A (en) 1995-06-07 1998-06-23 Peptor Limited Comformationally constrained backbone cyclized somatostatin analogs
US5708135A (en) 1995-09-29 1998-01-13 Biomeasure Incorporated Cyclic peptide analogs of somatostatin
US5750499A (en) 1995-10-18 1998-05-12 The Salk Institute For Biological Studies Receptor-selective somatostatin analogs
US5843903A (en) 1995-11-27 1998-12-01 The Administrators Of The Tulane Educational Fund Targeted cytotoxic anthracycline analogs
US6156725A (en) * 1996-08-16 2000-12-05 National Institute Of Immunology Drug for the treatment of cancer
JP2002506424A (ja) 1997-04-22 2002-02-26 キュレイター オブ ザ ユニバーシィティ オブ ミズーリ ガストリン受容体−親和性ペプチド結合体
AU4267700A (en) * 2000-01-13 2001-07-19 Academia Sinica Application of somatostatin analogs to specific delivery of anti-tumor drugs into tumor cells
CN101481405A (zh) * 2001-06-08 2009-07-15 研究及应用科学协会股份有限公司 生长激素释放抑制因子-多巴胺嵌合类似物

Also Published As

Publication number Publication date
AU2002341792B2 (en) 2007-09-06
ZA200402698B (en) 2005-04-25
WO2003028527A8 (en) 2004-04-15
CN1589151A (zh) 2005-03-02
BR0212897A (pt) 2004-08-24
WO2003028527A2 (en) 2003-04-10
MXPA04002621A (es) 2004-07-08
IL160993A0 (en) 2004-08-31
US7326685B2 (en) 2008-02-05
PL369336A1 (en) 2005-04-18
EP1435826A4 (en) 2009-07-15
JP2005505580A (ja) 2005-02-24
WO2003028527A3 (en) 2003-10-30
KR20040047846A (ko) 2004-06-05
EP1435826A2 (en) 2004-07-14
IL160993A (en) 2011-04-28
NZ532204A (en) 2006-04-28
US20050070470A1 (en) 2005-03-31
JP4799820B2 (ja) 2011-10-26
CA2461099A1 (en) 2003-04-10
NO20041186L (no) 2004-05-05

Similar Documents

Publication Publication Date Title
IS7189A (is) Sómatóstatín- eða bombesínhliðstæðusamstæður til greiningar eða meðferðar og notkun þeirra
DK1404809T3 (da) Forbedrede hudsubstitutter og anvendelser deraf
DE60237823D1 (de) Medizinisches behandlungsinstrument
NO20030832D0 (no) Kondenserte cykliske forbindelser og medisinsk anvendelse derav
EP1417988A4 (en) RESPIRATORY EQUIPMENT
DK1417175T3 (da) Substituerede dihydro-3-halo-1h-pyrazol-5-carboxylater og fremstillingog anvendelse heraf
NO20044195L (no) Biofosfoninsyrer for behandling og prevensjon av osteoprose
NO20035156D0 (no) Fremgangsmåter for brönnbehandling
NO20034159L (no) Östrogen-gestagen-kombinasjonspreparat og anvendelse derav
FR2846545B1 (fr) Implant d'osteosynthese intramedullaire
NO20051503D0 (no) Pyrazolopyridiner og fremgangsmater for fremstilling og anvendelse av de samme.
IL157328A0 (en) Treatment involving dkk-1 or antagonists thereof
GB0201674D0 (en) Medical treatment
DE60205718D1 (de) Flexibler wellschlauch und anschlussverfahren
DE60223576D1 (de) Hautbehandlungszusammensetzung
DE60227963D1 (de) Behandlungssystem
DK1355668T3 (da) Anvendelse af IL-18 inhibitorer til behandling og/eller forebyggelsen af hjertesygdom
IS7275A (is) Samsetning fyrir hollegg og notkun á henni
DE60220220D1 (de) Blutbehandlungssystem
DE60222664D1 (de) Hautbehandlungsmittel
SG106109A1 (en) Tomography or curved surfaces
DE60114244D1 (de) Osteosynthesevorrichtung
DE50209299D1 (de) Chirurgisches schälmesser
DE60228736D1 (de) Menschliches bmcc1-gen
ITBO20020613A1 (it) Apparecchiatura per il trattamento e la pulizia dentale.